Market open
Kronos Bio/$KRON
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kronos Bio
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
Ticker
$KRON
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
58
Website
Kronos Bio Metrics
BasicAdvanced
$54M
Market cap
-
P/E ratio
-$1.74
EPS
1.88
Beta
-
Dividend rate
Price and volume
Market cap
$54M
Beta
1.88
52-week high
$1.60
52-week low
$0.69
Average daily volume
58K
Financial strength
Current ratio
8.485
Quick ratio
8.212
Long term debt to equity
19.094
Total debt to equity
22.032
Interest coverage (TTM)
-116.80%
Management effectiveness
Return on assets (TTM)
-28.28%
Return on equity (TTM)
-63.00%
Valuation
Price to revenue (TTM)
6.314
Price to book
0.44
Price to tangible book (TTM)
0.44
Price to free cash flow (TTM)
-0.603
Growth
Revenue change (TTM)
172.76%
Earnings per share change (TTM)
-17.45%
3-year earnings per share growth (CAGR)
-17.96%
What the Analysts think about Kronos Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kronos Bio stock.
Kronos Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Kronos Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Kronos Bio News
AllArticlesVideos
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
GlobeNewsWire·2 weeks ago
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
GlobeNewsWire·4 weeks ago
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kronos Bio stock?
Kronos Bio (KRON) has a market cap of $54M as of November 08, 2024.
What is the P/E ratio for Kronos Bio stock?
The price to earnings (P/E) ratio for Kronos Bio (KRON) stock is 0 as of November 08, 2024.
Does Kronos Bio stock pay dividends?
No, Kronos Bio (KRON) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Kronos Bio dividend payment date?
Kronos Bio (KRON) stock does not pay dividends to its shareholders.
What is the beta indicator for Kronos Bio?
Kronos Bio (KRON) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.